GGrantIndex
← Leaderboards

Daniel Malamud

Pennsylvania State Univ Hershey Med Ctr

$17,592,139
Attributed
$19,539,122
Total exposure
10
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY200516
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$26,101,572 · 11

By mechanism

U01$11,944,576 · 2
U19$7,893,485 · 3
R01$6,183,614 · 3
P01$58,217 · 1
R13$20,000 · 1
P41$1,680 · 1

Top collaborators

Most similar at Pennsylvania State Univ Hershey Med Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Antiviral Agents

Research focus

Antiviral AgentsSalivaOralLeadViralBaseClinical ResearchIn VitroTissuesHiv InfectionsVariantHiv-1Transmission ProcessHiv Envelope Protein Gp120BacteriaProgramsSamplingSpecificityBinding (Molecular Function)VaginaDesignFemaleVirusBinding Sites

Grant awards (40)

The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$723,472
R01 · FY2016 · AI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$732,548
R01 · FY2015 · AI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$492,342
R01 · FY2014 · AI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$181,467
U19 · FY2014 · DE · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$492,342
R01 · FY2013 · AI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$1
R01 · FY2013 · AI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$896,761
R01 · FY2012 · AI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$1,272,576
U19 · FY2011 · DE · contact PI
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition$556,500
R01 · FY2011 · AI
Functional Studies of Soluble Innate Host Factors in HIV and Bacteria$244,433
U19 · FY2011 · DE · contact PI
CROSSTALK AMONG ORAL & GASTROINTESTINAL SOLUBLE INNATE FACTORS, HIV, & MICROBES$1,680
P41 · FY2011 · RR · contact PI
Point Detection of Pathogens in Oral Samples via UPT$1,774,102
U01 · FY2010 · DE · contact PI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$1,292,217
U19 · FY2010 · DE · contact PI
Functional Studies of Soluble Innate Host Factors in HIV and Bacteria$251,026
U19 · FY2010 · DE · contact PI
Point Detection of Pathogens in Oral Samples via UPT$1,766,971
U01 · FY2009 · DE · contact PI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$1,282,604
U19 · FY2009 · DE · contact PI
Functional Studies of Soluble Innate Host Factors in HIV and Bacteria$244,485
U19 · FY2009 · DE · contact PI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$1,256,065
U19 · FY2008 · DE · contact PI
Point Detection of Pathogens in Oral Samples via UPT$873,450
U01 · FY2008 · DE · contact PI
Functional Studies of Soluble Innate Host Factors in HIV and Bacteria$243,940
U19 · FY2008 · DE · contact PI
Point Detection of Pathogens in Oral Samples via UPT$1,661,021
U01 · FY2007 · DE · contact PI
Crosstalk Among Oral & Gastrointestinal Soluble Innate Factors, HIV, & Microbes$1,277,521
U19 · FY2007 · DE · contact PI
Functional Studies of Soluble Innate Host Factors in HIV and Bacteria$241,813
U19 · FY2007 · DE · contact PI
Administrative Core$105,338
U19 · FY2007 · DE · contact PI
Point Detection of Pathogens in Oral Samples via UPT$1,859,595
U01 · FY2006 · DE · contact PI
Oral-Based Diagnostics$20,000
R13 · FY2006 · DE · contact PI
Point Detection of Pathogens in Oral Samples via UPT$963,343
U01 · FY2005 · DE
Anti-HIV Activity of Lung SRCR (gp-340) in Saliva$332,151
R01 · FY2005 · DE
Point Detection of Pathogens in Oral Samples via UPT$1,036,527
U01 · FY2004 · DE
Anti-HIV Activity of Lung SRCR (gp-340) in Saliva$396,250
R01 · FY2004 · DE
Point Detection of Pathogens in Oral Samples via UPT$1,010,661
U01 · FY2003 · DE
Anti-HIV Activity of Lung SRCR (gp-340) in Saliva$396,250
R01 · FY2003 · DE
Point Detection of Pathogens in Oral Samples via UPT$998,906
U01 · FY2002 · DE
Anti-HIV Activity of Lung SRCR (gp-340) in Saliva$396,250
R01 · FY2002 · DE
DEVELOPMENT OF C31G AS A TOPICAL MICROBICIDE$0
P01 · FY2002 · AI
SUBMANDIBULAR SALIVARY PROTEINS SPECIFICALLY INHIBIT HIV$394,948
R01 · FY2001 · DE
DEVELOPMENT OF C31G AS A TOPICAL MICROBICIDE$0
P01 · FY2001 · AI
DEVELOPMENT OF C31G AS A TOPICAL MICROBICIDE$0
P01 · FY2001 · AI
SUBMANDIBULAR SALIVARY PROTEINS SPECIFICALLY INHIBIT HIV$373,799
R01 · FY2000 · DE
DEVELOPMENT OF C31G AS A TOPICAL MICROBICIDE$58,217
P01 · FY2000 · AI